Effect of pentoxifylline in severe sepsis: Results of a randomized, double-blind, placebo-controlled study

Archives of Surgery

Volumn 133, Issue 1, 1998, Pages 94-100

  Staubach, Karl Hermann ^a   Schröder, Jörg ^b   Stüber, Frank ^b,d   Gehrke, Katrin ^b   Traumann, Emanuel ^a   Zabel, Peter ^c  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c RESEARCH CENTER BORSTEL   (Germany)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT INDICATION;

APACHE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; SEPSIS; SHOCK, SEPTIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0031962714     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.133.1.94     Document Type: Article

References (41)

1. Ayres SM. SCCM's new horizons conference on sepsis and septic shock. Crit Care Med. 1985;13:864-866.
2. Fong Y, Lowry SF. Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol. 1990;55:157-170.
3. Christman JW, Holden EP, Blackwell TS. Strategies for blocking the systemic effects of cytokines in the sepsis syndrome. Crit Care Med. 1995;23:955-963.
4. Cohen J, Carlet J. Intersept: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med. 1996;24:1431-1440.
5. Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis receptor: Fc fusion protein. N Engl J Med. 1996;334:1697-1702.
6. Bone RC. Monoclonal antibodies to tumor necrosis factor in sepsis: help or harm? Crit Care Med. 1993;21:311-312.
7. Sullivan GW, Carper HT, Novick WJ, Mandell GL. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor alpha on neutrophil function by pentoxifylline. Infect Immun. 1988;56:1722-1729.
8. Dettelbach HR, Aviado DM. Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication. J Clin Pharmacol. 1985;25:8-26.
9. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 1991;110: 192-198.
10. Noel P, Nelson S, Bokulie R, et al. Pentoxifylline inhibits lipopolysaccharideinduced serum tumor necrosis factor and mortality. Life Sci. 1990;47:1023-1029.
11. Zabel P, Wolter DT, Schönharting MM, Schade FU. Oxpentifylline in endotoxaemia. Lancet. 1989;2:1474-1477.
12. Poggesi L, Scarti L, Boddi M, Masotti G, Serneri GGN. Pentoxifylline treatment in patients with occlusive peripheral arterial disease: circulatory changes and effects on prostaglandin synthesis. Angiology. 1985;36:628-637.
13. Zheng J, Crowly J, Chang JH, et al. Attenuation of tumor necrosis factorinduced endothelial cell cytotoxicity and neutrophil chemoluminescence. Am Rev Respir Dis. 1990;142:1073-1078.
14. Chalkiadakis GE, Kostakis A, Karayannacos PE, et al. Pentoxifylline in the treatment of experimental peritonitis in rats. Arch Surg. 1985;120:1141-1144.
15. Harada H, Ishizaka A, Yonemaru M, et al. The effects of aminophylline and pentoxifylline on multiple organ damage after Escherichia coli sepsis. Am Rev Respir Dis. 1989;140:974-980.
16. Lilly CM, Sandhu JS, Ishizaka A, et al. Pentoxifylline prevents tumor necrosis factor-induced lung injury. Am Rev Respir Dis. 1989;139:1358-1361.
17. Schade UF. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock. 1990;31:171-181.
18. Boldt J, Müller M, Heyn S, Welters I, Hempelmann G. Influence of long-term continuous intravenous administration of pentoxifylline on endothelial-related coagulation in critically ill patients. Crit Care Med. 1996;24:940-946.
19. Montravers P, Fagon JY, Gilber C, Blanchet F, Novara A, Chastre J. Pilot study of cardiopulmonary risk from pentoxifylline in adult respiratory distress syndrome. Chest. 1993;103:1017-1022.
20. Zeni F, Pain P, Vindimian M, et al. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit Care Med. 1996;24: 207-214.
21. Bone RC, Sprung CL, Sibbald WJ. Definitions for sepsis and organ failure. Crit Care Med. 1992;20:724-726.
22. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638-1652.
23. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818-829.
24. Sturk A, Janssen ME, Muylaert FR, Joop K, Thomas LLM, ten Cate JW. Endotoxin testing in blood. In: Detection of Endotoxins With a Limulus Amebocyte Lysate Test. New York, NY: Alan R Liss Inc; 1987:371-385.
25. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 subclone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods. 1986;95:99-105.
26. Aarden LA, de Groot ER, Schaap OL, Lansdorp PM. Production of hybridoma growth factor by human monocytes. Eur J Immunol. 1987;17:1411-1416.
27. Bryce TA, Burrows JL. Determination of oxpentifylline and a metabolite, 1-(5′hydroxyhexyl)-3-7-dimethylxanthine, by gas-liquid chromatography using a nitrogen-selective detector. J Chromatogr. 1980;181:355-361.
28. Fisher CJ, Zheng Y. Potential strategies for inflammatory mediator manipulation: retrospect and prospect. World J Surg. 1996;20:447-453.
29. Sibbald WJ, Vincent JL. Round table conference on clinical trials for the treatment of sepsis. Grit Care Med. 1995;23:394-399.
30. Bone RC, Sprung CL, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapy in sepsis. Crit Care Med. 1992;20: 724-726.
31. Stüber F, Petersen M, Bokelmann F, Schade FU. A genomic polymorphism within tumor necrosis factor locus influences plasma tumor necrosis factor-a concentrations and outcome of patients with severe sepsis. Crit Care Med. 1996;24:381-384.
32. Freudenberg MA, Galanos C. Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice. Infect Immun. 1991;59:2110-2115.
33. Hoffmann H, Hatherill JR, Crowley J, et al. Early post-treatment with pentoxifylline or dibutryl cAMP attenuates Escherichia coli-induced acute lung injury in guinea pigs. Am Rev Respir Dis. 1991;143:289-293.
34. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;318:1481-1486.
35. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. TNF soluble receptors protect against excessive TNF alpha during infection and injury. Proc Natl Acad Sci U S A. 1992;89:4845-4849.
36. Fong Y, Moldawer LL, Shires GT, Lowry SF. The biological characteristics of cytokines and their implications in surgical injury. Surg Gynecol Obstet. 1990;170: 363-378.
37. Suffredini AF. Current prospects for the treatment of clinical sepsis. Crit Care Med. 1994;20(suppl):S12-S18.
38. Ridings PC, Windsor ACJ, Sugerman HJ, et al. Beneficial cardiopulmonary effects of pentoxifylline in experimental sepsis are lost once septic shock is established. Arch Surg. 1994;129:1144-1152.
39. DeVault GA, Kohan DE, Nelson EW, Holman JM. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3. Transplantation. 1994;57:532-540.
40. Carter MB, Wilson MA, Wead WB, Garrison RN. Pentoxifylline attenuates pulmonary macromolecular leakage after intestinal ischemia-reperfusion. Arch Surg. 1995;130:1337-1344.
41. Wang P, Ba ZF, Zhou M, Tait SM, Chaudry IH. Pentoxifylline restores cardiac output and tissue perfusion after trauma-hemorrhage and decreases susceptibility to sepsis. Surgery. 1993;114:352-359.